R
Raffaele Bruno
Researcher at University of Pavia
Publications - 322
Citations - 14690
Raffaele Bruno is an academic researcher from University of Pavia. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 52, co-authored 275 publications receiving 11262 citations. Previous affiliations of Raffaele Bruno include University of Modena and Reggio Emilia.
Papers
More filters
Journal ArticleDOI
OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon‐naïve patients with HIV/HCV genotype 2/3 co‐infection in Italy
Raffaele Bruno,Giuseppe Cariti,Paola Nasta,Amedeo Capetti,Veronica Ravasio,Massimo Galli,E. Raise,G. Palmieri,Claudio Iannacone,Massimo Puoti +9 more
TL;DR: To determine SVR and other response rates, identify SVR predictors and analyse differences between G2 and G3 with PEG‐IFN/RBV in a large HIV/HCV G2/3 patient population is analyzed.
Journal ArticleDOI
COVID-19 and breast cancer: may the microbiome be the issue?
Angioletta Lasagna,Valentina Zuccaro,Elisa Ferraris,Marta Corbella,Raffaele Bruno,Paolo Pedrazzoli +5 more
TL;DR: This research presents a novel and scalable approach to diagnosis and treatment of central nervous system diseases through a probabilistic approach that combines traditional and innovative methods.
Journal ArticleDOI
Prevalence and histologic features of transfusion transmitted virus and hepatitis C virus coinfection in a group of HIV patients
Raffaele Bruno,Paolo Sacchi,M. Debiaggi,S.F.A. Patruno,Francesca Zara,Valentina Ciappina,Enrico Brunetti,Carlo Filice,Cristina Zocchetti,E. Maffezzini,Angela Pistorio,Gaetano Filice +11 more
TL;DR: Transfusion-transmitted virus infection is common in human immunodeficiency virus patients and its clinical role in the pathogenesis of liver disease was evaluated in patients with transfusion- transmitted-virus hepatitis C virus coinfection compared with those with hepatitis C Virus infection alone.
Journal ArticleDOI
Costo efficacia di peginterferone α-2a + ribavirina verso peginterferone α-2b + ribavirina nel trattamento dell’epatite cronica di tipo C in pazienti non pretrattati
TL;DR: In this article, the authors evaluated the cost-effectiveness of peginterferon α-2a plus ribavirin versus peginTERferon β-2b plus ribvirin in the treatment of chronic hepatitis C in HIV-HCV co-infection.